Sortilin

Sortilin Molekülinformation

Englischer Name	Sortilin	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	100 kDa NT receptor，NT3，Glycoprotein 95，LDLCQ6，NTR3，Gp95，Sortilin 1，Neurotensin receptor 3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Sortilin
Target-Alias	100 kDa NT receptor，NT3，Glycoprotein 95，LDLCQ6，NTR3，Gp95，Sortilin 1，Neurotensin receptor 3
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Sortilin Produktliste

Attribut
Protein (5)Cell (1)
Produktbibliothek
Online (6)
Spezies
Human (3)Cynomolgus (1)Rat (1)Canine (1)
Etikett
His Tag (4)His Tag & Avi Tag (1)- (1)
Marker
Unconjugated (4)Biotin-labeled (1)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
CHEK-ATP155	Human	HEK293	HEK293/Human SORT1 Stable Cell Line	In den Warenkorb legen
SON-H52H5	Human	HEK293	Human Sortilin / SORT1 Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
SON-H82E9	Human	HEK293	Biotinylated Human Sortilin / SORT1 Protein, His,Avitag™ (MALS & SPR verified)	In den Warenkorb legen
SON-C52H3	Cynomolgus	HEK293	Cynomolgus Sortilin Protein, His Tag	In den Warenkorb legen
SON-C52H4	Canine	HEK293	Canine Sortilin Protein, His Tag	In den Warenkorb legen
SON-R52H3	Rat	HEK293	Rat Sortilin Protein, His Tag (MALS verified)	In den Warenkorb legen

Gesamtmenge6

Produktanfrage

Sortilin Molekülhintergrund

Sortilin is a multifunctional type-I transmembrane protein belonging to the Vps10p-domain receptor family (Vps10p-Domain Receptors, Vps10p-DRs). Sortilin plays a central role in cellular protein sorting, signal transduction, and metabolism. Its dysfunction is closely related to neurodegenerative diseases, metabolic syndrome, and cancer, and it is a potential therapeutic target for diseases.

Sortilin Molekülalias

Sortilin,SORT1,100 kDa NT receptor,Glycoprotein 95,Gp95,Gp95LDLCQ6,Neurotensin receptor 3,NT3NTR3,Ntr3,sortilin 1,

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
VES-001	VES001; VES-001	Phase 2 Clinical	Vesper Bio APS	Dementia; Frontotemporal Dementia; Frontotemporal Lobar Degeneration	Details
Latozinemab	AL-001; GSK-4527223	Phase 1 Clinical	Alector Inc, Glaxosmithkline Plc	Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Neurodegenerative Diseases	Details
ARB-1-6	ARB-1-6; PQ-203	Phase 1 Clinical	ProteinQure Inc	Breast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details